Homepage
from science to hope.
Opening new frontiers in brain health.
HOPE was our large-scale study to test how our science could help people with mild-to-moderate Alzheimer’s preserve the everyday abilities they depend on.
Learn moreThe results could help preserve the everyday abilities that matter most.
82%
Slowing of decline in function
(ADCS-ADL)
Per protocol adherence population.*
The What Matters Most Framework.
To understand what the HOPE findings could mean for people and families, we translated clinical results into everyday life. The What Matters Most framework, created by leading Alzheimer’s advocacy organizations, helped us show the HOPE findings through the everyday abilities people value most.
Spectris is Cognito’s scientific platform, designed to synchronize brain activity.
The HOPE Study examined whether this approach could have the potential to preserve cognition, function and the abilities we depend on to think, remember, connect, and participate in everyday life for people with mild-to-moderate Alzheimer’s.
Beginning with Alzheimer’s, we’re working towards better brain health for everyone.
*The per-protocol group includes participants who used Spectris for at least 6 months, completed a full one-hour session on at least 5 days a week on average, and followed the main study rules.
Sabbagh MN, Kern RZ, Zusterzeel R, Hamilton RH. Spectris Treatment in Mild-to-Moderate Alzheimer’s Disease: Topline Results and Secondary Analyses From the HOPE Pivotal Study. Presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference; November 16-19, 2026; Boston, Massachusetts.